{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T07:04:05Z","timestamp":1648796645880},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:00:00Z","timestamp":1540339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00347-018-0803-0","type":"journal-article","created":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T09:57:35Z","timestamp":1540375055000},"page":"785-788","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cobimetinib\u2011\/Vemurafenib-assoziierte bilaterale ser\u00f6se Retinopathie: ein Fallbericht"],"prefix":"10.1007","volume":"116","author":[{"given":"Gregor","family":"Kastl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,24]]},"reference":[{"key":"803_CR1","volume-title":"Cotellic + Zelboraf: Adverse drug reactions guide for healthcare providers. Stand: 2017","author":"Genentech USA, Inc","year":"2017","unstructured":"Genentech USA, Inc (2017) Cotellic + Zelboraf: Adverse drug reactions guide for healthcare providers. Stand: 2017. \n                    https:\/\/www.cotellic.com\/content\/dam\/gene\/cotellic\/hcp\/PDFs\/ADR_Guide_Website_Resource.pdf\n                    \n                  . Zugegriffen: 28. Juni 2018"},{"issue":"1","key":"803_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jfo.2015.05.009","volume":"39","author":"A Coutu","year":"2016","unstructured":"Coutu A, Farguette F, Jeannin G et\u00a0al (2016) Chorior\u00e9tinopathie s\u00e9reuse multifocale secondaire \u00e0 l\u2019utilisation des inhibiteurs MEK: illustration et exemple de prise en charge \u00e0 travers 2\u00a0cas. J\u00a0Fran\u00e7ais d\u2019Ophtalmologie 39(1):55\u201363. \n                    https:\/\/doi.org\/10.1016\/j.jfo.2015.05.009","journal-title":"J Fran\u00e7ais d\u2019Ophtalmologie"},{"issue":"Suppl 6","key":"803_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.5301\/EJO.2010.6049","volume":"21","author":"J Cunha-Vaz","year":"2011","unstructured":"Cunha-Vaz J, Bernardes R, Lobo C (2011) Blood-retinal barrier. Eur J Ophthalmol 21(Suppl 6):S3\u2013S9. \n                    https:\/\/doi.org\/10.5301\/EJO.2010.6049","journal-title":"Eur J Ophthalmol"},{"key":"803_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12967-017-1246-0","volume":"15","author":"L Cruz-Merino De la","year":"2017","unstructured":"De la Cruz-Merino L, Di Guardo L, Grob J\u2011J et al (2017) Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. J\u00a0Transl Med 15:146. \n                    https:\/\/doi.org\/10.1186\/s12967-017-1246-0","journal-title":"J Transl Med"},{"key":"803_CR5","volume-title":"Fachinformation Cotellic\u00ae 20\u202fmg. Stand: M\u00e4rz 2018. Zulassungsnummer EU\/1\/15\/1048\/001","author":"Roche Pharma AG, Grenzach-Wyhlen","year":"2018","unstructured":"Roche Pharma AG, Grenzach-Wyhlen (2018) Fachinformation Cotellic\u00ae 20\u202fmg. Stand: M\u00e4rz 2018. Zulassungsnummer EU\/1\/15\/1048\/001. \n                    https:\/\/www.roche.de\/dok\/Cotellic-reg-Filmtabletten-fachinfo-0-na-attach.pdf\n                    \n                  . Zugegriffen: 27. Juni 2018"},{"issue":"6","key":"803_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40257-017-0292-y","volume":"18","author":"AM Grimaldi","year":"2017","unstructured":"Grimaldi AM, Simeone E, Festino L et\u00a0al (2017) MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. Am J Clin Dermatol 18(6):745\u2013754. \n                    https:\/\/doi.org\/10.1007\/s40257-017-0292-y","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"803_CR7","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3892\/ijmm_00000191","volume":"23","author":"Q Jiang","year":"2009","unstructured":"Jiang Q, Cao C, Lu S et al (2009) MEK\/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med 23(6):771\u2013777. \n                    https:\/\/doi.org\/10.3892\/ijmm_00000191","journal-title":"Int J Mol Med"},{"issue":"3","key":"803_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1152\/physrev.00021.2004","volume":"85","author":"O Strauss","year":"2005","unstructured":"Strauss O (2005) The retinal pigment epithelium in visual function. Physiol Rev 85(3):845\u2013881. \n                    https:\/\/doi.org\/10.1152\/physrev.00021.2004","journal-title":"Physiol Rev"},{"issue":"18","key":"803_CR9","doi-asserted-by":"publisher","first-page":"e3457","DOI":"10.1097\/MD.0000000000003457","volume":"95","author":"EH Dijk van","year":"2016","unstructured":"van Dijk EH, Duits DE, Versluis M et al (2016) Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients. Medicine (Baltimore) 95(18):e3457. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000003457","journal-title":"Medicine (Baltimore)"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-018-0803-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-018-0803-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T20:12:54Z","timestamp":1571861574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-018-0803-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,24]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1007\/s00347-018-0803-0","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,24]]},"assertion":[{"value":"24 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Kastl gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}